Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?

More and more clinical trials have explored the role of liquid biopsy in the diagnosis and treatment of EGFR-mutated NSCLC. In certain circumstances, liquid biopsy has unique advantages and offers a new way to detect therapeutic targets, analyze drug resistance mechanisms in advanced patients, and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi-Ze, Kong, Sheng-Nan, Liu, Yun-Peng, Yang, Yue, Zhang, Hong-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966257/
https://www.ncbi.nlm.nih.gov/pubmed/36835972
http://dx.doi.org/10.3390/jcm12041438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966257/
https://www.ncbi.nlm.nih.gov/pubmed/36835972
http://dx.doi.org/10.3390/jcm12041438

Ejemplares similares